New drug trial targets rare and Tough-to-Treat cancers
NCT ID NCT06788938
Summary
This study is testing an investigational drug called tarlatamab in adults with advanced cancers that have a specific protein called DLL3. The goal is to see if the drug is safe and can shrink these hard-to-treat tumors. Participants will receive the drug until their cancer worsens or they experience unacceptable side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UC Davis Comprehensive Cancer Center
RECRUITINGDavis, California, 95817, United States
Contact Email: •••••@•••••
Contact
-
UC San Diego Moores Cancer Center
RECRUITINGSan Diego, California, 92093, United States
Contact Email: •••••@•••••
Contact
-
UCI Health Chao Family Comprehensive Cancer Center
RECRUITINGIrvine, California, 92612, United States
Contact
Contact Email: •••••@•••••
-
University of California at Los Angeles
RECRUITINGLos Angeles, California, 90095, United States
Contact Phone: •••-•••-••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University of California at San Francisco
RECRUITINGSan Francisco, California, 94143, United States
Contact
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.